Slideshow

What’s New in Lupus: 3 Potential Targets for Therapy

Author(s):

Mark L. Fuerst

Researchers have set their sights on macrophage activation syndrome, pathways identified in renal cells, and mechanistic target of rapamycin.

References1. Borgia RE, Gerstein M, Levy DM, et al. Features, treatment, and outcomes of macrophage activation syndrome in childhood‐onset systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:616-624. doi: 10.1002/art.40417.2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Accelerating Medicines Partnership (AMP). Accessed May 22, 2018.3. Kato H, Perl A. Blockade of Treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:427-438. doi: 10.1002/art.40380.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Related Content
Orrin Troum, MD, clinical professor of medicine, Keck School of Medicine, University of Southern California, and director, clinical rheumatology research, Providence St John's Hospital, Santa Monica, California
November 22nd 2024

Shortened Pegloticase Infusions Feasible for Uncontrolled Gout, Reduces Treatment Burden

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Søren Andrea Just, MD, PhD, associate professor, University of Southern Denmark, and Odense University Hospital – Svendborg.
November 21st 2024

AI Assessments, Robotics Perform to Rheumatologist Levels in Joint Assessment

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Megan Clowse, MD, MPH, Associate Professor of Medicine, Associate Professor in Obstetrics and Gynecology, and Associate Professor in Population Health Sciences, and Chief of the Division of Rheumatology and Immunology, Duke University School of Medicine
November 19th 2024

DZP Improves Disease Activity and Reduces Corticosteroid Use in SLE

Victoria Johnson
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
November 19th 2024

Vagus Nerve Stimulation Yields Responses in Refractory Rheumatoid Arthritis

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.